NP49425 Generic and Biosimilar Transition Medicines

Estimated value

£131.2m

goods

Awarded value

Suppliers

0

Lots

9

0 awarded

Published

05 Aug 2025

This is a preliminary market engagement notice

Map the supplier landscape and document your shortlist before opening the tender. The market simulation produces a defensible audit record you can attach to your procurement file.

Run market simulation

Total lots

9

Awarded

0

9 pending

Estimated total

£234.9m

Awarded total

Lot 8planned

Cancer Medicines (Group 2)

Estimated
£15.2m

Start

01 Feb 2026

End

31 Jan 2027

Estimated

£15.2m

CPV

33600000
No suppliers awarded yet for this lot.
Lot 1planned

Cytokine Modulators

Estimated
£100.0m

Start

01 Feb 2026

End

28 Feb 2027

Estimated

£100.0m

CPV

33600000
No suppliers awarded yet for this lot.
Lot 2planned

Gastrointestinal, Endocrine, Nutrition, Blood, and Multiple Sclerosis Medicines

Estimated
£15.6m

Start

31 Mar 2026

End

28 Feb 2027

Estimated

£15.6m

CPV

33600000
No suppliers awarded yet for this lot.
Lot 3planned

Denosumab (osteoporosis)

Estimated
£26.2m

Start

01 Feb 2026

End

31 Jul 2027

Estimated

£26.2m

CPV

33600000
No suppliers awarded yet for this lot.
Lot 4planned

Apremilast

Estimated
£27.4m

Start

01 Feb 2026

End

31 Jul 2027

Estimated

£27.4m

CPV

33600000
No suppliers awarded yet for this lot.
Lot 5planned

Cardiovascular and Respiratory Medicines

Estimated
£1.5m

Start

01 Feb 2026

End

31 Oct 2027

Estimated

£1.5m

CPV

33600000
No suppliers awarded yet for this lot.
Lot 6planned

Nintedanib

Estimated
£457k

Start

01 Feb 2026

End

30 May 2028

Estimated

£457k

CPV

33600000
No suppliers awarded yet for this lot.
Lot 7planned

Cancer Medicines (Group 1)

Estimated
£27.3m

Start

31 Mar 2026

End

30 May 2028

Estimated

£27.3m

CPV

33600000
No suppliers awarded yet for this lot.
Lot 9planned

Neurology Medicines

Estimated
£21.3m

Start

01 Feb 2026

End

31 Jan 2027

Estimated

£21.3m

CPV

33600000
No suppliers awarded yet for this lot.